For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and Attruby represents a genuine breakthrough . These groundbreaking therapies protect the transthyretin protein, slowing its destructive build-up and reducing the impact of the condition . People are now reporting positive o… Read More